SCHEMBL31397238

SCHEMBL31397238

Cn1c(=O)n(-c2ccc(OCc3ccccc3)nc2OCc2ccccc2)c2ccc(N3CCN(C(=O)OC(C)(C)C)CC3=O)cc21

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TLR9 Q9NR96 4/20 0.38
▸ GPR119 Q8TDV5 4/20 0.38
▸ TLR7 Q9NYK1 2/20 0.38
▸ P2RX3 P56373 1/20 0.35
▸ GRM5 P41594 1/20 0.34
▸ ACHE P22303 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ CCNA1 P78396 1/20 0.34
▸ ENPP2 Q13822 2/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ PRMT5 O14744 2/20 0.33
▸ SLC2A1 P11166 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ CXCR3 P49682 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23541288 0.90 GPR119 (0.47) TLR9GPR119TLR7ACHEENPP2
SCHEMBL30273831 0.86 GPR119 (0.43) TLR9GPR119TLR7PRMT5
SCHEMBL30273940 0.86 GPR119 (0.43) TLR9GPR119TLR7PRMT5
SCHEMBL24819665 0.86 GPR119 (0.43) TLR9GPR119TLR7PRMT5
SCHEMBL25036627 0.86 GPR119 (0.43) TLR9GPR119TLR7PRMT5
SCHEMBL23540305 0.85 GPR119 (0.47) TLR9GPR119TLR7PRMT5
SCHEMBL30274078 0.85 GPR119 (0.37) TLR9GPR119TLR7GRM5ACHE
SCHEMBL25175944 0.84 GRM5 (0.43) TLR9GPR119TLR7P2RX3GRM5
SCHEMBL30273826 0.84 CYP11B2 (0.39) TLR9GPR119TLR7GRM5ACHE
SCHEMBL30273975 0.84 GPR119 (0.39) TLR9GPR119TLR7ACHEPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424111-A1 Degrader Compounds and Uses Thereof CALICO LIFE SCIENCES LLC (US) 2024-12-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240424111-A1 Degrader Compounds and Uses Thereof PTPN1, PTPN2, PTPN5 TLR9 3300/4885GPR119 1060/4885TLR7 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback